| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Wyeth |
| Information provided by: | Wyeth |
| ClinicalTrials.gov Identifier: | NCT00494962 |
Purpose
To determine the bioequivalence between two 5-mg tablets of lecozotan and the new 10-mg tablet of lecozotan.
| Condition | Intervention | Phase |
|
Alzheimer Disease |
Drug: lecozotan SR |
Phase I |
| Genetics Home Reference related topics: | Alzheimer disease |
| MedlinePlus related topics: | Alzheimer's Disease |
| Drug Information available for: | Lecozotan |
| Study Type: | Interventional |
| Study Design: | Health Services Research, Randomized, Open Label, Dose Comparison, Crossover Assignment, Bio-equivalence Study |
| Official Title: | An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study Between Two 5-mg Tablets and a New 10-mg Tablet Formulation of Lecozotan SR in Healthy Subjects. |
Eligibility
| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
Exclusion criteria:
Contacts and Locations More Information
| Study ID Numbers: | 3098B1-1147 |
| First Received: | June 29, 2007 |
| Last Updated: | December 3, 2007 |
| ClinicalTrials.gov Identifier: | NCT00494962 |
| Health Authority: | Germany: Ethics Commission; Germany: Federal Institute for Drugs and Medical Devices |
|
|
|
|
